A randomized phase I study of <scp>BI</scp> 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low‐dose liraglutide in otherwise healthy men with overweight or obesity
BI 1820237 treatment was associated with transient nausea and vomiting at higher doses. No differences in tolerability were observed when combined with liraglutide; effects on gastric emptying appeared additive.
Authors
- Nadine Beetz (ORCID: https://orcid.org/0000-0002-1071-7000)
- Anita M. Hennige (ORCID: https://orcid.org/0000-0002-5149-4966)
- Thomas Först (ORCID: https://orcid.org/0000-0003-2132-5691)
- Armin Schultz
- Brigitte Kalsch
- B. Schmid (ORCID: https://orcid.org/0009-0008-4516-3467)
Institutions
- Boehringer Ingelheim (Germany) (DE)
- Clinical Research Services (DE)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1111/dom.15984
- Citations
- 7
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.69